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Neurobiology of Disease
Soluble -Amyloid1–40 Induces NMDA-Dependent
Degradation of Postsynaptic Density-95 at
Glutamatergic Synapses
F. Roselli,1,2M. Tirard,1 J. Lu,1 P. Hutzler,3 P. Lamberti,2 P. Livrea,2M.Morabito,4 and O. F. X. Almeida1
1Max Planck Institute of Psychiatry, 80804 Munich, Germany, 2Department of Neurological and Psychiatric Sciences, University of Bari, 70124 Bari, Italy,
3Institute of Pathology, GSF National Research Center for Environment and Health, 85764 Neuherberg, Germany, and 4Department of Cell Biology,
University of Massachusetts Medical School, E. K. Shriver Center, Waltham, Massachusetts 02452
Amyloid- (A) has been implicated in memory loss and disruption of synaptic plasticity observed in early-stage Alzheimer’s disease.
Recently, it hasbeen shown that solubleAoligomers target synapses in cultured rat hippocampalneurons, suggesting adirect role ofA
in the regulation of synaptic structure and function. Postsynaptic density-95 (PSD-95) is a postsynaptic scaffolding protein that plays a
critical role in synaptic plasticity and the stabilization of AMPA (AMPARs) and NMDA (NMDARs) receptors at synapses. Here, we show
that exposure of cultured cortical neurons to soluble oligomers of A1–40 reduces PSD-95 protein levels in a dose- and time-dependent
manner and that theA11–40-dependentdecrease inPSD-95 requiresNMDARactivity.Wealso show that thedecrease inPSD-95 requires
cyclin-dependent kinase 5 activity and involves the proteasomepathway. Immunostaining analysis of cortical cultured neurons revealed
that A treatment induces concomitant decreases in PSD-95 at synapses and in the surface expression of the AMPARglutamate receptor
subunit 2. Together, these data suggest a novel pathway by which A triggers synaptic dysfunction, namely, by altering the molecular
composition of glutamatergic synapses.
Key words: phosphorylation; glutamate receptor; metabotropic glutamate receptor; AMPA receptor; synaptic plasticity; amyloid ; A
peptide; NMDA receptor; PSD-95; proteasome; cdk5
Introduction
Insoluble amyloid- (A1–40 and A1–42) fibrils, generated from
the cleavage of amyloid precursor protein, constitute the extra-
cellular senile plaques that typify the brains of patients with Alz-
heimer’s disease (AD); plaque formation is a protracted process.
However, recent studies have shown that soluble, low-molecular-
weight (8–24 kDa) A oligomers, referred to as amyloid-derived
diffusible ligands, may be responsible for initiating neuronal dys-
function (Lambert et al., 1998; Walsh et al., 2002; Gong et al.,
2003) (for review, seeMattson, 2004). Soluble A peptides can be
detected, albeit in low amounts, in normal brain (Lue et al., 1999)
in which they seem to play a physiological role (Wilquet and De
Strooper, 2004). Notwithstanding that neuronal loss is seen in
later stages ofAD, an emerging view is that synaptic failure is a key
pathogenic factor in the disease (Selkoe, 2002). Strong evidence
links reductions in synaptic density with severity of dementia
(DeKosky and Scheff, 1990; Coleman and Yao, 2003), and, inter-
estingly, changes in synaptic density have been recorded in ter-
minal, distal dendrites in the frontal cortex at very early stages of
disease (Coleman et al., 2004). Thus, impairment in synaptic
function and plasticity might be an early event in the pathogen-
esis of Alzheimer’s disease (Oddo et al., 2003; Walsh and Selkoe,
2004; Wang et al., 2004).
Postsynaptic density-95 (PSD-95) is an abundant postsynap-
tic scaffolding protein that plays an important role in synapse
maturation and synaptic plasticity (El-Husseini et al., 2000).
PSD-95 is implicated in the assembly of many components of the
PSD, including downstream signalingmolecules and cytoskeletal
linker proteins (McGee and Bredt, 2003; Kim and Sheng, 2004).
Palmitoylation of PSD-95 is required for the synaptic localization
and clustering of PSD-95 (Christopherson et al., 2003; McGee
and Bredt, 2003).Morabito et al. (2004) have shown that T19 and
S25 residues in the N-terminus of PSD-95 are phosphorylated in
a cyclin-dependent kinase 5 (cdk5)-dependent manner and that
inhibition of cdk5 in neurons results in larger PSD-95 clusters.
These observations suggest that cdk5 regulates the number/den-
sity of PSD-95 clusters at synapses (Morabito et al., 2004).
PSD-95 interacts directly with NMDA receptors (NMDARs),
modulating their channel properties (Iwamoto et al., 2004; Lin et
al., 2004) and posttranslational processing (Dong et al., 2004)
and stabilizing them at synapses (Niethammer et al., 1996; Roche
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et al., 2001; Lavezzari et al., 2003; Li et al., 2003; Lin et al., 2004).
Recent studies have shown that PSD-95 interacts indirectly with
AMPA receptors (AMPARs) through the transmembrane pro-
tein stargazin (L. Chen et al., 2000; Schnell et al., 2002) and reg-
ulates the trafficking and localization of AMPARs at synapses
(McGee and Bredt, 2003). Activity-mediated internalization of
AMPARs is inhibited by PSD-95 and requires the binding of
PSD-95 to stargazin (L. Chen et al., 2000; Schnell et al., 2002).
Furthermore, overexpression of PSD-95 enhances AMPAR-
mediated synaptic transmission and occludes long-term potenti-
ation (LTP) (Stein et al., 2003; Ehrlich andMalinow, 2004). Col-
ledge et al. (2003) demonstrated that, in response to NMDAR
activation, PSD-95 is ubiquitinated and rapidly removed from
synaptic sites by proteasome-dependent degradation. Mutations
that block PSD-95 ubiquitination prevent NMDA-induced
AMPAR endocytosis, suggesting a key role for PSD-95 degra-
dation in the induction of long-term depression (LTD). The
importance of PSD-95 in cognitive processes is attested by the
observation that PSD-95 knock-out mice show impaired spatial
learning abilities (Migaud et al., 1998) and that PSD-95 is driven
in synapses during experience-induced plasticity (Ehrlich et al.,
2004).
Recently, Lacor et al. (2004) demonstrated that A oligomers
bind to synaptic sites that are immunopositive for PSD-95. Given
the importance of PSD-95 in synaptic function, we examined its
possible involvement in A-associated changes in glutamatergic
synapses. Our results suggest that degradation of PSD-95 con-
tributes to alterations in synaptic plasticity that are observed in
the pathogenesis of Alzheimer’s disease.
Materials andMethods
Drugs and peptides. A1–40 was from American Peptides (Sunnyvale,
CA); A1–40 peptide was dissolved in DMSO at 2 mM and then diluted
1:10 in sterile PBS, vortexed for 30min [at room temperature (RT)], and
centrifuged at 15,000 g at 4°C for 1 h; the supernatant (200 M) was
aliquoted (25 l) and snap frozen at 20°C. Unless stated differently,
aliquotswere diluted in culturemedium to a final concentration of 10M
immediately before use. The predominant aggregates in such prepara-
tions are reported to be low N-oligomers (mainly monomeric to tet-
rameric) (Walsh et al., 1997; Bitan et al., 2001, 2003; Stine et al., 2003).
Although the possibility that our preparation contained aminor amount
of protofibrils cannot be excluded, it should be noted that fibrillogenesis
requires longer incubation times and higher concentrations (10M) of
the peptide (O’Nuallain et al., 2004; Wogulis et al., 2005).
NMDA, ()-verapamil, chloroquine, and KN-93 (2-[N-(2-hydroxy-
ethyl)]-N-(4-methoxybenzenesulfonyl)amino-N-(4-chlorocinnamyl)-
N-methylbenzylamine) were purchased from Sigma (Deisenhofen, Ger-
many). Bicuculline, MK-801 [()-5-methyl-10,11-dihydro-5H-
dibenzo [a,d] cyclohepten-5,10-imine maleate], ifenprodil, 2,3-
dihydroxy-6-nitro-7-sulfonyl-benzo[f]quinoxaline (NBQX), E4CPG
[(RS)--ethyl-4-carboxyphenylglycine], and CPPG [(RS)--cyclopro-
pyl-4-phosphono-phenyl-glycine] were from Tocris Cookson (Bristol,
UK). 6-Aminopyridine-sulfonamide (PNU 112455A; cdk2/5 inhibitor),
2,4-dibenzyl-5-oxothiadiazolinidine-3-thione [TDZT; glycogen syn-
thase kinase-3 (GSK-3) inhibitor], and MG132 (z-Leu-Leu-Leu-al)
(proteasome inhibitor) were purchased fromCalbiochem (La Jolla, CA).
U0126 [1,4-diamino-2,3-dicyano-1,4-bis(o-aminophenylmercapto)
butadiene] (extracellular signal-regulated kinase 1/2 inhibitor) was from
Cell Signaling Technology (Beverly, MA).
Primary cell culture. Cortical primary cell cultures were prepared by
dissociating frontal cortical tissue from postnatal day 4 (P4) Wistar rats
(Charles River Wiga, Sulzfeld, Germany) with trypsin [0.05% in Earle’s
balanced salt solution (EBSS) with 0.3% bovine serum albumin (BSA);
Invitrogen, Eggenstein, Germany]. Neurons were isolated from
trypsinized frontal cortex tissue after centrifugation on a one-step BSA
(4%) density gradient (Crochemore et al., 2005). Frontal cortex was
isolated by dissection, after complete removal ofmeninges. Isolated brain
tissue was triturated mechanically, digested with trypsin (0.05% in
EBSS), triturated gently, and transferred to Neurobasal/B27 medium
containing 1% fetal calf serum (FCS) and 0.2% BSA at 37°C. Triturated
tissue was filtered through a sterile nylon mesh (30 mm pore size) and
centrifuged at 200 g (20°C, 5 min) before resuspension in Neurobasal/
B27 medium containing 0.1% ovomucoid/0.005% DNase I (Worthing-
ton, Freehold, NJ). Aliquots of this suspensionwere stratified on 4%BSA
containing 0.1% ovomucoid and centrifuged at 70  g (20°C, 5 min).
Cells were plated in Neurobasal/B27medium containing basic fibroblast
growth factor (10 ng/ml), glutamax I (0.5 mM), and kanamycin (100
mg/ml) (all from Invitrogen) onto gelatin/poly-D-lysine-coated glass
coverslips at a density of 450,000 cells/mm2. Cultures were incubated at
37°C, under 5% CO2/95% air and 90% relative humidity. Half of the
culture medium was renewed every 3 d. Experiments were started 7 d
after seeding [7 d in vitro (DIV)].
SK-N-MC cell line cultures. Human neuroblastoma SK-N-MC cells
were maintained at 37°C (5% CO2/95% air) in DMEM containing 10%
FCS (Invitrogen) and 1% kanamycin. Cells (200 103) were seeded on
six-well plates 1 d before use.
Transfection. SK-N-MC cells were transfected with 500 ng of DNA per
well using jet-PEI (Polytransfection, Illkirch, France), as described pre-
viously (Tirard et al., 2004). After 24 h, cells were fed with fresh medium
before application of drugs.
Western blot. Cells were lysed by brief sonication in 100 mM Tris-HCl,
250 mM NaCl, 1 mM EDTA, 5 mM MgCl2, 1% NP-40, a mixture of
protease inhibitors (Complete Protease Inhibitor; Roche, Mannheim,
Germany), and a phosphatase inhibitor mixture (Phosphatase Inhibitor
Cocktails I and II; Sigma), before centrifugation. Cleared lysates were
resolved by electrophoresis on 8% acrylamide gels and transferred onto
nitrocellulose membranes. Membranes were blocked in PBS containing
5% nonfat milk powder and 0.2% Tween-20 and incubated with the
following antibodies: anti-PSD-95 (1:6000; Upstate Biotechnology, Lake
Placid, NY), anti-synapsin I (1:500; Chemicon, Temecula, CA), anti-
cdk5 (1:1000; Biomol, Plymouth Meeting, PA), anti-GAP-43 (1:5000;
Chemicon), and anti-actin (1:10,000; Chemicon) or anti--tubulin (1:
2000; Oncogene Sciences, Uniondale, NY). Antigens were revealed by
enhanced chemiluminescence (Amersham Biosciences, Freiburg, Ger-
many) after incubation with appropriate horseradish peroxidase–IgG
conjugates (Amersham Biosciences); blots were scanned and quantified
usingTINA3.0 bioimaging software (Raytest, Straubenhardt, Germany).
Linearity was routinely checked during semiquantification of all blots.
All values were normalized and expressed as percentages of control; in
pharmacological experiments, percentages were calculated as A treated
versus A untreated. Each set of numerical data shown were obtained
from three to five independent sets of experiments, with three replicates
in each run.
DNA constructs. Wild-type PSD-95 and triple alanine (T19A, S25A,
S35A) mutant PSD-95 were in pcDNA3 expression vectors (Morabito et
al., 2004). Wild-type PSD-95 and PSD-95PEST [PSD-95 mutant in
which the PEST motif (amino acids 13–23) was deleted] in pGW1-
cytomegalovirus expression vectors were kindly provided by Dr. Marcie
Colledge (Vollum Institute, Portland, OR).
Immunofluorescence. Cells were fixed in ice-cold 4% paraformalde-
hyde (5 min), rinsed in PBS, and permeabilized in PBS containing 0.1%
Triton X-100 and 5% horse serum (at RT). All reagents and incubations
were in PBS containing 0.1%Triton X-100 and 3%BSA. Coverslips were
blocked (10% horse serum in PBS) and incubated overnight (4°C) with
anti-PSD-95 (1:500). After thorough washing, coverslips were incubated
with biotinylated goat anti-mouse IgG (1:500; Molecular Probes, Eu-
gene, OR) for 1 h (at RT) and rinsed in PBS before incubation with
FITC-conjugated streptavidin (diluted 1:500; Molecular Probes). To
double stain for synapsin I, cells were incubated (overnight, 4°C) with
rabbit anti-synapsin I (1:500; Chemicon), rinsed in PBS, and incubated
at RT (1 h) in biotinylated goat anti-rabbit IgG (1:500). Coverslips were
stained with Texas Red-conjugated streptavidin (1:500; Molecular
Probes). For glutamate receptor subtype 2 (GluR2) surface immuno-
staining, cells were washed with PBS (at RT) and incubated (40 min, on
ice) with anti-GluR2 antibody (1:150; Chemicon) diluted in PBS. After
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washing, cells were fixed in ice-cold 4% paraformaldehyde, pH 7.4,
blocked with PBS containing 10% horse serum, incubated (overnight,
4°C) with biotinylated goat anti-mouse IgG (1:500; Molecular Probes)
diluted in PBS containing 10% horse serum, rinsed, and stained with
FITC-conjugated streptavidin (1:500; Molecular Probes). Coverslips
were mounted with Vectashield (Vector Laboratories, Burlingame, CA).
Optical section images and stacks of images from fluorescence-labeled
cells were obtained with a confocal laser scanningmicroscope (LSM 510;
Zeiss, Jena, Germany) using a plan apochromat 63/1.4 numerical ap-
erture oil lens. PSD-95 immunostaining was monitored in 200 puncta
within 12 randomly chosen dendrites from four neurons (triplicate spec-
imens). To evaluate puncta density, images were thresholded at the arbi-
trary value of 50, and puncta density was expressed as puncta number per
100 m. Immunofluorescence intensity of manually selected PSD-95
synaptic puncta was evaluated on synapsin I-labeled samples using Scan-
Image software (Scion, Frederick, MD) after subtracting background
intensity value in each region of interest. For evaluating surface-bound
AMPAR immunostaining, 225 positive puncta were measured within 10
randomly chosen dendrites from five neurons (triplicate determina-
tions), with fluorescence intensity and puncta density being quantified as
described above.
Statistical analysis. All data are depicted as mean  SD from three to
five independent experiments. Data were analyzed for statistical signifi-
cance using ANOVA and appropriate post hoc tests (Student–Keuls or
Kruskal–Wallis multiple comparison procedures, as appropriate) in
which p 0.05 was set as the minimum level of significance.
Results
A1–40 decreases levels of PSD-95 but not of other
synaptic proteins
Synthetic oligomerized A1–42 and A1–40, as well as natural A
oligomers, were recently shown to disrupt LTP induction (Q. S.
Chen et al., 2000;Walsh et al., 2002;Wang et al., 2002; Kamenetz
et al., 2003;Wang et al., 2004; Klyubin et al., 2004). To investigate
the pathway(s) through which Amight impair synaptic plastic-
ity, we monitored the expression of several synaptic proteins in
rat primary cortical neuronal cultures. Neurons were exposed to
10 M freshly-dissolved A1–40 for 15, 60, or 120 min. (Fig. 1A),
and proteinswere detected byWestern blot analysis of cell lysates.
Levels of synapsin I, AMPAR subunit GluR2, GAP-43, cdk-5, and
calcium/calmodulin-dependent kinase II (CaMKII) protein ex-
pression were unaltered by A treatment at all time points stud-
ied. Neither actin nor tubulin expression were affected by these
treatments. In contrast, application of A resulted in a 53.3 
6.5%decrease in PSD-95 levels at 60min ( p 0.05), and PSD-95
levels remained significantly lower (76 10.9%; p 0.05) after
120 min when compared with untreated cultures (100%). We
next examined whether the A effects on PSD-95 expression oc-
curred in a dose-dependent manner. Treatment of cortical neu-
rons with 100 nM, 1 M, or 10 M A for 60 min resulted in
PSD-95 levels that were, respectively, 81.9 3.6, 73.2 3.4, and
51  5.5% of those found in controls (Fig. 1B). Pairwise com-
parisons between all groups revealed significant differences ( p
0.05), and linear regression analysis of the dose–response curve
yielded an r of 0.879 ( p	 0.007).
PSD-95 is predominantly localized at synapses in which it
plays an important role in activity-dependent remodeling of neu-
ronal connections (Okabe et al., 1999; Ehlers, 2003). To assess
whether synaptic PSD-95 is affected by A treatment, cortical
neurons (7 DIV) were treated with soluble A (10 M, 60 min)
and immunostained for synapsin I (a marker of presynaptic ter-
minals) and PSD-95. Quantitative immunofluorescence analysis
of confocal images was conducted blind, as described byColledge
et al. (2003). Treatment with A did not affect fluorescence in-
tensity of synapsin I-immunoreactive puncta (89.9  25.4% of
Figure 1. PSD-95 levels are reduced after A treatment in rat primary cortical neurons. A,
A selectively downregulates PSD-95 levels in a time-dependentmanner, without altering the
expression of other synaptic proteins. Cells were exposed to 10M soluble A1–40 (see Mate-
rials andMethods) for between15and120minbefore analysis byWesternblot. As shown in the
histogram, semiquantitative evaluation of PSD-95 levels, normalized against tubulin, shows
that A treatment led to a significant reduction of PSD-95 expression (53.3 6.5% of control
levels; p 0.05) within 60min; despite a trend to recover by 120min after treatment, PSD-95
expression remained significantly lower than in controls (76 10.9%; p 0.05). Analysis of
levels of the synaptic proteins GluR2, GAP-43, synapsin I, cdk5, and CaMKII revealed no signifi-
cant effect of A over the treatment duration. Actin and tubulin levels were not influenced by
the experimental manipulations. B, Dose-dependent effects of A on PSD-95 levels. Neurons
were exposed to A (0.1–10 M) for 1 h before they were analyzed for levels of PSD-95
expression in Western blot assays. One representative Western blot is shown, and the semi-
quantitative data from three independent experiments are shown in the histogram. Levels of
PSD-95, normalizedwith respect to tubulin levels, are shownasmeans SD. Asterisks indicate
significant changes fromuntreated control cells ( p 0.05). The dose–response curve had r	
0.879 ( p	 0.007). C, A effect on synaptic PSD-95. Primary rat cortical neurons were treated
with10MA for 1h, fixed, and immunostained for synapsin I andPSD-95. Synaptic siteswere
identified as synapsin I-positive puncta. Puncta density in vehicle-treated control cultures was
36 2.4 puncta/100m; after A treatment, the density of PSD-95 immunoreactive puncta
was 24.6 2.1/100m ( p 0.001). Numerous synaptic sites (identified by synapsin stain-
ing) showed prominent decreases in PSD-95 fluorescence after A treatment; fluorescence
intensity of synaptic PSD-95 was reduced after A treatment (49.4 2.4% compared with
100 6.7% in controls; p 0.01, p 0.05; n	 200). Scale bars, 5m. All numerical data
represent mean SD.
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control). However, as Figure 1C shows, A
treatment decreased both the density of syn-
aptic PSD-95 puncta (36 2.4 vs 24.6 2.1
puncta/100 m in vehicle-treated and A-
treated cultures, respectively; p 0.05) and
the intensity of synaptic PSD-95-labeled
puncta (49.4  2.4 compared with 100 
6.7% in controls; p 0.01). These observa-
tions indicate that A targets PSD-95 in a
sizeable subset of synapses.
A-induced downregulation of PSD-95
depends on NMDAR activity and is
Ca2 dependent
A peptides modulate glutamate receptor
activity (Ye et al., 2004), and NMDAR ac-
tivity leads to decreased PSD-95 protein
levels (Colledge et al., 2003). To test the
role of NMDARs in the effects of A on
PSD-95 levels, P4 cortical neurons were
pretreated (1 h) with either the NMDAR
antagonist MK-801 (10 M) or the NR2B-
specific antagonist ifenprodil (10 M) be-
fore being exposed to A. Subsequent
Western blot analysis of cell lysates re-
vealed that both MK-801 and ifenprodil
inhibited A-induced downregulation of
PSD-95 levels (106.1  3.1 and 115.4 
13.4%, respectively; PSD-95 levels in un-
treated controls, 100%) (Fig. 2A), indicat-
ing that NMDAR activation is required for
manifestation of the A effects. Consistent
with this observation, treatment with 10
M NMDA (1 h) and A did not signifi-
cantly alter PSD-95 levels compared with
A alone. Next, because NMDAR activa-
tion results in Ca2 influx, we tested the
importance of extracellular Ca2 for A-
induced downregulation of PSD-95. No
significant changes in PSD-95 were de-
tected when neurons were treated with A
under Ca2-free conditions (106.5 19.1
vs 50 10.5% reduction of PSD-95 levels
when A was added in standard medium)
(Fig. 2B). Verapamil (100 M) did not
block the effects of A, indicating that
Ca2 influx through L-type voltage-
dependent calcium channels is not in-
volved (data not shown).
Glutamate receptors other than
NMDARs have also been shown to regu-
late PSD-95 levels; thus, whereas AMPAR activation results in
reduced PSD-95 levels (Bingol and Schuman, 2004), activation of
the metabotropic glutamate receptor mGluR1 increases PSD-95
levels (Todd et al., 2003). Pretreatment (1 h) of neurons with the
AMPAR antagonist NBQX (20 M) did not interfere with the
ability of A to reduce PSD-95 levels (A, 56.8 7.6%vsA plus
NBQX, 61.9  9.1%) (Fig. 2C); likewise, blockade of group I
mGluRs with E4CPG (10 M) did not alter the ability of A to
reduce PSD-95 levels (49.8 15%) (Fig. 2D). Interestingly, treat-
ment of neurons with CPPG (10 M), an antagonist of metabo-
tropic glutamate receptors mGluRII/III, significantly attenuated
the effects of A on PSD-95 levels (81.4  15%) (Fig. 2D). Be-
causemGluRII/III negatively regulate glutamate release, we next ex-
amined the effects of A under conditions of increased glutamater-
gic drive by applying theGABAA receptor antagonist bicuculline (40
M). Bicuculline treatment significantly attenuated the A-induced
decrease in PSD-95 levels (97.7 9.6%) (Fig. 2C), suggesting that
increased excitatory activity can override A-dependent regulation
of PSD-95 levels activity; it also suggests thatmGluRII/III can exert a
modulatory effect in this process.
cdk5 activity is required for A-induced decreases in PSD-95
PSD-95 is a target of mitogen-activated protein kinase (MAPK)
(Sabio et al., 2004) and cdk5 (Morabito et al., 2004). cdk5 and its
Figure2. A-inducedPSD-95downregulation requiresNMDARactivity and calcium influx.A, A-induceddecrease in PSD-95
levels requires NMDAR activity. Cells treated with A showed a significant decrease in PSD-95 levels (67.5 6.7%; p 0.05 vs
untreated cells). Treatment (1 h) of cells with MK-801 (10 M) or ifenprodil (10 M) prevented the A-induced decrease in
PSD-95 levels, whereas NMDA (10M) did not influence the effects of A (59 5%; p 0.05 comparedwith nontreated cells).
C, Control. B, PSD-95 downregulation by A is a calcium-dependent process. Neurons exposed to A (10 M; 1 h) under
calcium-free conditions did not show a reduction in PSD-95 levels compared with untreated control cells. C, The PSD-95 down-
regulating actions of A are not dependent on AMPAR and are attenuated by bicuculline. Neurons were pretreated (1 h) with
NBQX (20M), bicuculline (40M), or vehicle before exposure to A (10M; 1 h). NBQX proved ineffective in counteracting A
action (61.9 9.1%), whereas bicuculline attenuated the effects of A on PSD-95 levels (81.4 15%; p 0.05 vs A alone).
D, The A-induced decrease in PSD-95 levels is blocked in the presence of ametabotropic II/III receptor antagonist. Neuronswere
pretreated (1 h) with the mGluRI/II antagonist E4CPG (E4) (10M), the mGluRII/III antagonist CPPG (10M), or vehicle before
treatment with A (10M) for an additional 1 h. E4CPG did not alter the actions of A on PSD-95, whereas CPPG significantly
antagonized the A effect (81.4 15%; p 0.05 vs response to A only). Asterisks indicate significant changes fromuntreated
control cells (p 0.05). All data are given as mean SD.
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activators p35 and p39 are localized postsynaptically (Humbert et
al., 2000; Niethammer et al., 2000; Morabito et al., 2004) and can
regulate GSK3 (Morfini et al., 2004). Furthermore, NMDAR
activation can lead to activation of cdk5 (Kerokoski et al., 2004),
and cdk5 can also be activated by A1–40 peptide (Cruz et al.,
2004). To evaluate the role of various kinases in the A-induced
reduction in PSD-95 levels, we pharmacologically inhibited the
activity of kinases putatively involved in the regulation of PSD-95
using human neuroblastoma cell line (SK-
N-MC) for screening; this cell line ex-
pressesMAPK, cdk5, CaMKII, andGSK3
(data not shown) and functional NMDA
receptors (Pizzi et al., 2002; Deiva et al.,
2004). Because SK-N-MC cells display
low-to-undetectable PSD-95 levels, we
transiently transfected these cells with
wild-type PSD-95 plasmid. Neither trans-
fections of PSD-95 nor pharmacological
treatments affected endogenous levels of
the kinases studied (data not shown). Ex-
posure of cells expressing heterologous
PSD-95 to A (10 M, 1 h) resulted in a
significant reduction in PSD-95 levels
(58.31 8.2% of controls; p 0.05) (sup-
plemental Fig. 1A,B, available at www.j-
neurosci.org as supplemental material);
the magnitude of changes was comparable
with those observed inA-treated primary
neurons (compare Figs. 1A, 2A). Treat-
ment with inhibitors of CaMKII (KN-93),
GSK-3 (TDZT), and MAP kinase kinase
1/2 (U0126) did not alter the effect of A
on PSD-95 (54.2  7, 57.4  29, and
65.2  6.2%, respectively). In contrast,
pharmacological inhibition of cdk5 with
10 M PNU 112455A prevented A-
induced downregulation of PSD-95
(105.4 22%) (supplemental Fig. 1, avail-
able at www.jneurosci.org as supplemental
material).
To further investigate the role of the
cdk5-dependent phosphorylation of
PSD-95 in mediating the effect of A, we
transiently expressed the triple alanine
mutant of full-length PSD-95 (T19A,
S25A, S35A) (Morabito et al., 2004) in the
human neuroblastoma cell line (SK-N-
MC). Transient transfection of these cells
with wild-type PSD-95 plasmid and expo-
sure to A (10 M, 1 h) resulted in a sig-
nificant reduction in PSD-95 levels
(58.31 8.2% of controls; p 0.05) (Fig.
3B); themagnitude of changeswas compa-
rable with those observed in A-treated
primary neurons (Fig. 3A). Whereas A
led to a significant decrease in the expres-
sion levels of wild-type PSD-95 (57.9 
5.6%), this treatment did not influence
mutant PSD-95 levels (107.7  11.2%)
(Fig. 3B), suggesting that the integrity of
the N-terminal domain of PSD-95 is re-
quired for PSD-95 downregulation by A.
To further substantiate cdk-5 involve-
ment in A-induced PSD-95 downregulation, rat primary corti-
cal neurons were treated with two structurally unrelated cdk5
inhibitors, roscovitine (15 M) and PNU 112455A (10 M), or
vehicle (DMSO), for 1 h before the addition of A peptide (10
M) for 1 h. Both inhibitors prevented A-induced downregula-
tion of PSD-95 levels (104.1  16.8 and 99.9  8.2%, respec-
tively) (Fig. 3A), indicating that cdk5 activity is critical in the
regulation of PSD-95 by A in primary neurons. To confirm a
Figure 3. A-induced downregulation of synaptic PSD-95 requires cdk5 activity.A, cdk5 activity is necessary for A effects in
cortical neurons. Primary rat cortical neurons were pretreated (1 h) with roscovitine (15M) or PNU 112455A (10M), or vehicle
(DMSO) before exposure to A (10M; 1 h). As shown byWestern blotting, both inhibitors abrogated the ability of A to reduce
PSD-95 levels. C, Control.B, A cannotdownregulatePSD-95 levelswhenSK-N-MCcells are transiently transfectedwith theT19A,
S25A, S35A phosphorylation mutant of PSD-95. Cells transfected with wild-type PSD-95 and expressing p35/cdk5 responded to
Awith the expected decrease in PSD-95 levels (57.9 5.6% of controls; p 0.05). C, The A effects on synaptic PSD-95 are
blocked by roscovitine, an inhibitor of cdk5 activity. Primary rat cortical neuronswere pretreated (1 h)with roscovitine (15M) or
vehicle (DMSO) before exposure to A (10 M; 1 h). After fixation, neurons were immunostained for synapsin I and PSD-95.
Roscovitine alonedid not showa significant effect on thedensity of PSD-95puncta or their fluorescence intensity but inhibited the
effects of Aon these parameters. Scale bar, 5m.Asterisks indicate significant changes fromuntreated control cells (p0.05).
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role for cdk5 in the downregulation of the
synaptic pool of PSD-95, cortical neurons
were pretreated with roscovitine (15 M)
or vehicle before exposure to A peptide
(10 M, 1 h) and subsequent immuno-
staining for PSD-95 and synapsin I. Image
analysis revealed that roscovitine mark-
edly attenuated the effect of A on synap-
tic PSD-95 puncta density (35.3  4.7
puncta/100 m after roscovitine plus A
vs 24.6  2.1 puncta/100 m after A
treatment alone; p  0.05) and intensity
(90.1  12.4% after roscovitine plus A;
49.4  2.4% after A alone; and 100 
6.7% in treatment-free conditions; p 
0.05), whereas neither DMSOnor roscovi-
tine alone significantly altered synaptic
PSD-95 puncta density and intensity (Fig.
3C); however, cdk5 inhibition increased
the size of PSD-95 puncta (cf. Morabito et
al., 2004). Together, these experiments
strongly implicate cdk5 in mediating the
effect of A on the regulation of synaptic
PSD-95 levels.
Involvement of proteasome pathway in
A-induced reduction of PSD-95 levels
The proteasome has recently emerged as a
key regulator of PSD protein composition
and turnover (Ehlers, 2003). Activation of
NMDARs and AMPARs is followed by
PSD-95 degradation by the proteasome
(Colledge et al., 2003; Bingol and Schuman, 2004).Having shown
that A-induced PSD-95 downregulation depends on previ-
ous NMDAR activation, we were prompted to analyze whether
the pathway downstream of A involves the proteasome-
dependent degradation. To this end, SK-N-MC cells express-
ing heterologous wild-type PSD-95 were incubated with
MG132 (0.1 M), an inhibitor of the proteasome, chloroquine
(100 M), a lysosome inhibitor, or vehicle (DMSO), before
treatment with A (10 M, 1 h). Analysis of cell lysates by
Western blot revealed that MG132 treatment strongly attenu-
ated the effect of A on PSD-95 levels (control, 100%; A,
65.2 9.8%; MG132, 104.6 13.7%), whereas PSD-95 levels
after chloroquine treatment did not differ significantly
(71.7  6%) from those found in cells treated with A alone
(Fig. 4A). Consistent with these observations, pretreatment (1
h) of cortical neurons with MG132 before the addition of A
(10 M) abolished A-induced reductions in PSD-95 expres-
sion (data not shown), providing additional evidence that the
proteasome pathway is involved in the regulation of PSD-95
by A.
Ubiquitinylation is a posttranslational modification that tar-
gets proteins to the proteasome (DiAntonio and Hicke, 2004).
The N-terminal domain of PSD-95 contains a PESTmotif that is
essential for its ubiquitination (Colledge et al., 2003). To deter-
mine whether the PEST motif is important in the regulation of
PSD-95 by A, SK-N-MC cells were transfected with a mutant of
PSD-95 (PSD-95PEST) that lacks the PEST sequence. Control
cells that were transfected with wild-type PSD-95 responded to
A with a significant reduction in PSD-95 protein levels (53.6
19.8%), whereas cells expressing PSD-95PEST were not af-
fected by A treatment (102.6  5.8%) (Fig. 4B). Thus, the in-
tegrity of the N-terminal domain of PSD-95 is essential for the
effect of A on PSD-95.
A decreases the surface expression of AMPARs
Trafficking and synaptic targeting of AMPARs are important de-
terminants of synaptic strength (LTP or LTD) (Bredt and Nicoll,
2003). Previous studies have shown that PSD-95 regulates the
dynamics of AMPARs through interactions with stargazin
(Schnell et al., 2002); whereas PSD-95 overexpression drives AM-
PARs into synapses (Ehrlich et al., 2004), PSD-95 degradation is
followed by endocytosis of AMPARs (Colledge et al., 2003). To
assess whether the downregulation of PSD-95 induced byA also
affects the synaptic localization of AMPARs, we analyzed the sur-
face expression of GluR2, an AMPAR subunit, in cultured corti-
cal neurons (7 DIV) that had been exposed to A for 1 h. In
agreement with the results of Western blot analysis, we observed
that A treatment did not significantly change the intensity of
total GluR2 immunostaining in permeabilized neurons (103.2
3.6%; data not shown). In contrast, A treatment induced a
marked reduction in the density of surface GluR2-positive
puncta (21.2 6.54 vs 55.5 7.2 puncta/100min controls; p
0.001) (Fig. 5A,B) and intensity of puncta immunostained for
surface GluR2 (38.6  11.6 vs 100  13.5% in controls; p 
0.001) (Fig. 5A,C). Furthermore, we found that pretreatment
with the cdk5 inhibitor roscovitine (15M) abolished the effect of
A on the density (53.5  8.2 vs 54  12.8 puncta/100 m in
roscovitine only-treated cells) and intensity of surface GluR2
(99.5  13.1% versus roscovitine alone) (Fig. 5A–C). Together,
these results show that A treatment of neurons results in a de-
crease in the surface expression of GluR2 in a cdk5-dependent
manner.
Figure 4. The proteasome pathway is implicated in the regulation of PSD-95 by A. A, PSD-95-transfected cultures were
pretreated (1 h) with a proteasome inhibitor (MG132; 0.1M), a lysosome inhibitor (chloroquine; 100M), or vehicle (DMSO)
before treatmentwith A (10M; 1 h).MG132 treatment prevented A-induced reductions in PSD-95,whereas chloroquine did
not exert a significant influence on the actions of A. C, Control. B, The PEST consensus sequence in PSD-95 is necessary for the
A-induced effects. SK-N-MC cultures that had been transfected with either wild-type PSD-95 or thePEST deletion mutant of
PSD-95 were exposed to A (10M; 1 h). Whereas A led to a reduction in PSD-95 levels in wild-type transfected cells (53.6
19.8%; p 0.05 vs non-A-treated controls), PSD-95 levels were unchanged in cells expressing thePEST mutant. Asterisks
indicate significant changes from untreated control cells (p 0.05).
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Discussion
A peptides play an unequivocal role in AD, being prominent
components of senile plaques. Although A1–42 is required for
plaque formation (McGowan et al., 2005) and can induce synap-
tic dysfunction (Wang et al., 2004), we focused our investigations
on A1–40, the most abundant A peptide in the healthy and
AD-afflicted brain. Although the physiological functions of
A1–40 are a matter of some conjecture (Kamenetz et al., 2003),
this peptide has been strongly implicated in synaptic loss in AD
patients (cf. Lue et al., 1999; McLean et al., 1999) and impaired
LTP in murine models (Klyubin et al., 2004). Moreover, the cor-
relation between plaque burden and cognitive impairment (Guil-
lozet et al., 2003) and between A1–42 and synaptic loss in hu-
mans are rather weak (Lue et al., 1999). Recent studies in animals
have established links between natural, as well as synthetic, solu-
ble A oligomers and cognitive impairment (Richardson et al.,
2003; Cleary et al., 2005), and A oligomers have been shown to
induce disruption of LTP (Q. S. Chen et al., 2000; Walsh et al.,
2002; Kamenetz et al., 2003; Klyubin et al., 2004; Wang et al.,
2004) but not LTD (Wang et al., 2002) induction. These obser-
vations suggest that excitatory synapses might be the early targets
of solubleA, a view supported by evidence that oligomerizedA
can bind to synaptic sites, namely, PSD-95-containing postsyn-
aptic sites (Lacor et al., 2004). In the present study, cortical neu-
rons were treated with soluble A1–40 so as to obtain a prepara-
tion containing low-molecular-weight oligomers (Walsh et al.,
1997; Bitan et al., 2001, 2003; Stine et al., 2003); it is unlikely that
our preparation contained a significant amount of A1–40 fibrils
(O’Nuallain et al., 2004; Wogulis et al., 2005).
Based on the aforementioned studies, we here addressed the
possibility that soluble A1–40 exerts its effects on synaptic plas-
ticity by regulating the molecular composition and stability of
excitatory synapses. We focused our studies on PSD-95, a key
player in the organization, function, and plasticity of excitatory
synapses (Ehrlich and Malinow, 2004; Kim and Sheng, 2004).
The importance of PSD-95 in cognitive processes is attested by
the observation that PSD-95 knock-out mice show impaired
learning abilities (Migaud et al., 1998). The dynamic manner in
which PSD-95 levels are regulated contributes to the key role of
the protein in synaptic plasticity: brief NMDAR activation in-
duces rapid PSD-95 proteasomal degradation, an event accom-
panied by AMPAR internalization (Colledge et al., 2003).
Experiments in this study indicate that soluble A induces a
decrease in PSD-95 levels in a time- and
dose-dependent manner, without altering
the expression of the presynaptic protein
synapsin I, the AMPAR subunit GluR2,
and the kinases CaMKII and cdk5. These
findings indicate that PSD-95 is a specific
target of A. Interestingly, the dose of A
that affects PSD-95 is within the range that
blocks LTP (Kamenetz et al., 2003; Wang
et al., 2004), suggesting a correlation be-
tween the reduction of PSD-95 levels and
the inhibition of LTP. The A effects oc-
curred within 1 h, i.e., within a period
shown previously to be required for the
manifestation of NMDAR- and AMPAR-
dependent alterations in PSD-95 turnover
(Colledge et al., 2003; Bingol and Schu-
man, 2004). We observed that, after initial
downregulation, PSD-95 levels returned
to control levels within 2 h of application
of A; although proteolysis of A cannot be ruled out, it is plau-
sible that adaptive mechanisms (cf. Turrigiano, 1999; Todd et al.,
2003) are recruited over time.
The ionotropic glutamate receptors AMPARs and NMDARs
have been implicated in the regulation of PSD-95. Although AM-
PARs contribute to the regulation of PSD-95 degradation (Bingol
and Schuman, 2004), the AMPAR antagonist NBQX failed to
modulate the effect of A on PSD-95 in the present study. Acti-
vation of NMDARs was reported previously to result in reduced
PSD-95 levels (Colledge et al., 2003). In investigations of the
relationship between NMDAR activation and A-induced
downregulation of PSD-95, we found that the specific NMDAR
inhibitor MK-801 abolishes the effect of A, indicating that
NMDAR activity is prerequisite for the A effects to occur. Sim-
ilar observations were made with ifenprodil, an NR2B subunit-
specific antagonist; the latter resultsmost likely reflect the relative
abundance of NR2B subunit in the early postnatal brain (Liu et
al., 2004). Furthermore, we demonstrated the Ca2 dependency
of the regulation of PSD-95 protein levels by A, consistent with
a role ofNMDARactivity inmediating theA effects (Fig. 2A,B).
Our study included an analysis of the role of othermodulators
of glutamatergic activity in the regulation of PSD-95 levels. Inter-
estingly, class ImGluR activation leads to increased PSD-95 levels
(Todd et al., 2003), and the mGluR5 (a class I mGluR) has been
implicated in A-induced disruption of LTP (Wang et al., 2004).
Activation of the predominantly postsynaptic class I mGluRs has
been linked to long-term synaptic plasticity, including LTP in-
duction. However, because E4CPG failed to modify the effects of
A, mGluRI does not appear to be required for A-induced
PSD-95 degradation in our experimental setting. In contrast,
treatment of neurons with CPPG, an antagonist of mGluRII/III,
significantly inhibited the effects of A onPSD-95 levels, suggest-
ing that class I and class II/III mGluRs play different roles in the
response to A. mGluRII/III are mainly presynaptic and nega-
tively regulate glutamate release (Grassi et al., 2002). Increased
synaptic activity and glutamate receptor activation (after block-
ade of mGluRII/III or of GABAA receptors) efficiently blocked
the effects of A on PSD-95 levels. These results suggest that
increased synaptic activity can override or prevent A-induced
PSD-95 degradation. Our findings that increased excitatory syn-
aptic activity can attenuate the actions of A appear to be at odds
with the fact that NMDAR activation failed to block A-induced
PSD-95 degradation. It should be noted, however, that an ensem-
Figure 5. A reduces the expression of surface AMPARs. Primary rat cortical neurons were immunostained for the AMPAR
subunit of the GluR2; permeabilization steps were excluded to ensure labeling of surface receptors. A, B, The density of GluR2-
positivepuncta (expressedas thenumber of punctaper 100m)was reducedafter A treatment (21.26.5 vs 55.57.2;p
0.001). A, C, A treatment led to a significant reduction in the intensity of immunofluorescence of GluR2 puncta (38.6 11.6%;
p 0.001; 225 puncta analyzed). Pretreatmentwith roscovitine (15M) abrogated the effects of A on these parameters ( p
0.05) but had no effect of its own. Scale bar, 5m. Asterisks indicate significant changes fromuntreated control cells (p 0.05).
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ble of glutamate receptors and downstream signal transduction
pathways is activated when glutamatergic synaptic activity is in-
creased (e.g., after treatment with mGluRII/III antagonists or
bicuculline) and that these may influence PSD-95 levels (cf. Col-
ledge et al., 2003). Also, it should be recalled that, depending on
the intensity and timing of synaptic activity, NMDAR can result
in the expression of either LTP or LTD (Malenka andBear, 2004);
thus, it is conceivable that strong excitatory drive blocks the
downregulation of PSD-95 levels by A, whereas weak stimula-
tion of NMDARs is inadequate in this respect. Our results are
consistent with the findings that prolonged increases in excita-
tory synaptic activity upregulate PSD-95 levels (Ehlers, 2003),
whereas transient NMDAR activation can induce PSD-95 degra-
dation (Colledge et al., 2003); we suggest that maximal reduc-
tions in PSD-95 levels occur when A is applied at 10M, result-
ing in an occlusion of additional NMDA effects.
The serine–threonine kinase cdk5 plays a prominent role in
the development of the nervous system (Dhavan and Tsai, 2001)
and has been implicated in the pathogenesis of AD (Cruz and
Tsai, 2004). Recent studies have shown that PSD-95 is phosphor-
ylated in a cdk5-dependentmanner (Morabito et al., 2004). In the
present study, we identify a novel role for cdk5 in the regulation
of A-induced effects on PSD-95 levels. We show that inhibition
of cdk5 by roscovitine inhibits the effect of A on PSD-95 protein
levels and that levels of PSD-95 do not decline after A treatment
of cultured cells expressing the triple alanine mutant form of
PSD-95 (T19A, S25A, S35A), which lacks phosphorylation sites.
Together, these experiments clearly implicate cdk5 in the regula-
tion of synaptic PSD-95 protein levels and establish an important
novel connection between cdk5 activity and the effects of A on
the molecular composition of glutamatergic synapses.
Proteins are degraded in the cell through activation of either
the proteasome or lysosome. The posttranslational tagging of
proteins with ubiquitin represents a major mechanism through
which proteins are targeted for proteasomal degradation (Di-
Antonio and Hicke, 2004). The proteasome pathway plays a ma-
jor role in synaptic protein turnover (Ehlers, 2003), and PSD-95
is ubiquitinated at synapses after brief activation of NMDARs
(Colledge et al., 2003). In our study, the proteasome inhibitor
MG132 markedly attenuated the ability of A to downregulate
PSD-95, indicating a role for the proteasome pathway in regulat-
ing the effect of A.Moreover, A failed to downregulate levels of
the PEST deletion mutant of PSD-95 in transiently transfected
cells. Because thismutant lacks both the ubiquitinationmotif and
one of the cdk5 phosphorylation sites (T19), failure to induce the
downregulation of the PEST PSD-95 mutant and the nonphos-
phorylatable triple alanine mutant form of PSD-95 indicates that
the integrity of the N-terminal domain of PSD-95 is essential for
the A-dependent regulation of PSD-95. Because chloroquine
failed to prevent A-induced downregulation of PSD-95,
lysosome-mediated degradation is clearly not involved in the reg-
ulation of PSD-95 levels by A.
PSD-95, which is predominantly localized at synapses, regu-
lates the expression of NMDAR and AMPAR expression at
postsynaptic membranes. Our study indicates that A treatment
of cortical cultured neurons leads to a significant decrease in the
density and intensity of synaptic puncta positive for PSD-95; this
finding is consistent with previous observations showing that
PSD-95-positive synaptic puncta are targeted by A peptides
(Lacor et al., 2004). PSD-95 is coupled to AMPARs through the
stargazin family of proteins (Schnell et al., 2002). Decreased
PSD-95 levels result in decreasedAMPAR localization at synapses
(Colledge et al., 2003), whereas PSD-95 overexpression drives
AMPAR incorporation into the postsynapticmembrane (Ehrlich
et al., 2004). Our immunocytochemical studies of cortical cul-
tured neurons indicate that A treatment results in downregula-
tion of the expression of surface GluR2 (an AMPAR subunit),
without changing the levels of total GluR2, as measured byWest-
ern blotting and immunostaining. Given the importance of
PSD-95 in the synaptic stabilization of AMPARs, it is likely that
the decrease in surface expression of GluR2 is attributable to an
increase in GluR2 endocytosis, following the downregulation of
synaptic PSD-95. Interestingly, cotreatment with roscovitine
prevents the downregulation of GluR2 surface expression by A,
implicating cdk5 in the regulation of the molecular composition
and function of synapses in AD.
Both synthetic A1–42 and naturally secreted A oligomers
were recently shown to rapidly (within 1 h) induce endocytosis of
NMDARs in rat cortical neurons (Snyder et al., 2005). Because
PSD-95 binding is known to prevent NMDAR endocytosis
(Roche et al., 2001), we tentatively suggest that A-induced
PSD-95 degradation might contribute to NMDAR endocytosis
and that PSD-95 degradation itself may result from A-induced
dissociation of PSD-95 from NMDARs.
The results presented here are consistent with the view that
exposure of neurons to A peptides alters the availability of
PSD-95 and, most likely, dendritic spine morphology. The regu-
lation of these proteinsmay constitute a physiological role for A
peptides, and genetic or other predisposing factors that result in
increased production of soluble A are likely to trigger patho-
genic mechanisms leading to AD. The A-dependent reduction
in synaptic PSD-95, which requires NMDAR activity, Ca2 in-
flux, cdk5 activity, and the proteasome pathway, eventually leads
to internalization of AMPARs. Because AMPARs are key players
in synaptic function, their surface downregulation could consti-
tute a crucial mechanism for the synaptic derangement induced
by A. The results of the present study, demonstrating that solu-
ble A can interfere with postsynaptic function, provide substan-
tial support to the view that soluble Amay be responsible for the
cognitive impairments observed in early-phase AD patients
(Walsh and Selkoe, 2004).
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